Press Releases

Please find the latest news from Origin Sciences:

 

14 March 2017

Origin Sciences’ OriCol™ to be used in HIV study

 

London and Cambridge, UK, 14 March 2017: Fred Hutchinson Cancer Research Center (Fred Hutch) has selected Origin Sciences’ novel mucosal sampling device OriCol™ for use in sample collection as part of a phase I HIV study.

The HVTN 116 study will see OriCol™ used in a study to test two experimental antibodies VCR01 and VCR01LS, both of which can recognise and block many of the different forms of HIV, and in previous studies have been shown to block HIV infection. The aim of the study will be to evaluate the safety, pharmacokinetics, and antiviral activity of VRC01 and VRC01LS in the serum and mucosa of healthy, HIV-uninfected adults.

The OriCol™ device will be used to collect mucosal samples from the rectum of the study subjects, which will then be measured for Immunoglobulin (IgG) levels to monitor patients’ responses to experimental treatment.

If successful, the study could further support use of these unique antibodies as part of a vaccine, a strategy currently used with diseases such as hepatitis A and B and chickenpox. The antibodies, VCR01 and VCR01LS, are copies of a rare antibody that was identified in the blood of an HIV patient, whose body was able to successfully control HIV infection for 15 years.

OriCol™ is a clinician led procedure, that has been used in over 3000 patients and is well accepted.  It collects a biomarker rich, mucosal sample from the rectum without the need for bowel preparation.

Paul Weinberger, CEO of Origin Sciences said: “Fred Hutch is one of the most innovative research centres in the world, and their research has had a significant impact in alleviating the burden of many diseases. We are delighted they have chosen the OriCol™ device to collect samples in what could be an incredibly important study in tackling a major global health issue.”

Origin Sciences is an SME based in Cambridge, UK that has developed The OriCol™ Sampling Device, enabling clinicians to quickly and easily collect a unique mucosal sample for detection and diagnosis of gastrointestinal diseases. The device is inserted through a proctoscope, and the membrane is inflated with air using a syringe. Samples collected with OriCol™ can be used in a range of downstream analyses including investigation of DNA (mutation detection and methylation analysis), proteins, antibodies and the microbiome.

Fred Hutch does not endorse the use of this product.

OriCol™ is a registered trademark of Origin Sciences Limited.

 ENDS

Notes to Editors:

For more information, please contact:

Tony Stephenson, Exitus Communications

This email address is being protected from spambots. You need JavaScript enabled to view it.

Tel: +44 (0)7899 796655

About Origin Sciences Limited

Origin Sciences is a medical technology company developing innovative devices and tests to aid the detection and diagnosis of gastrointestinal diseases. Origin Sciences is based in Cambridge and London, UK and was established in 2004. Origin Sciences has launched the OriCol™ device for reliable and superior clinical sampling of mucocellular rectal material. In addition, Origin Sciences has a portfolio of products in development including a test for the detection of colorectal cancer (CRC). Origin Sciences is ISO 13485 accredited and aims to be at the forefront of scientific breakthroughs in investigating gastrointestinal disease. For further information, please visit www.orginsciences.com

 


 

 

14th March 2016                                                                      

Origin Begins Calprotectin Validation Study

New study will improve diagnosis of Inflammatory Bowel Disease

London and Cambridge, UK, 14 March 2016: Origin Sciences Ltd, a medical technology company developing unique sampling devices and diagnostics for patients with gastrointestinal diseases, has initiated a study to validate its OriCol™ device for calprotectin testing. The study will compare calprotectin levels in stool and rectal mucus of patients with suspected or confirmed inflammatory bowel disease (IBD).

Testing for Calprotectin, a well-validated biomarker of inflammation, is recommended by NICE as a way to help doctors differentiate between patients with inflammatory bowel diseases (such as Crohn’s disease and ulcerative colitis) and irritable bowel syndrome.

This is a multi-centre, open, prospective, performance evaluation study, across a number of UK hospitals with John McLaughlin, Professor of Gastroenterology and Nutrition from Salford Hospital, as principle investigator.

OriCol™ is an innovative device that collects mucocellular material from the rectum. The sample can be taken quickly by a healthcare professional, saving patients a second clinic visit and avoiding them having to handle faeces. Choosing OriCol™ guarantees compliance so results will be available at the next consultation. Previous studies have shown the effectiveness of using OriCol™ to collect DNA, proteins and a range of recognised biomarkers, including calprotectin and haemoglobin. Studies have also shown that the OriCol™ sample is well suited to next generation sequencing for cancer, infectious disease and human microbiome research.

Paul Weinberger, CEO of Origin Sciences said: “OriCol™ is already being adopted for gastrointestinal research studies looking at the gut microbiome and diseases such as cancer and IBD. We are excited to be validating the device for calprotectin testing, which will expand our offering into clinical diagnostics for bowel disease. In future we anticipate that our products will improve compliance and enhance the effectiveness of colorectal cancer screening programmes.”

Since 2014 Origin has made significant progress in developing and commercialising its diagnostic technology. 2014 saw the launch of OriCol™, a sampling device for investigating gastrointestinal disease, while 2016 saw the company expand its commercial presence to South East Asia and the US, and launch its Microbiome Sampling Kit. In addition, the company has been active in expanding its scientific research and has published data showing the benefits of using OriCol™ compared to traditional methods for research into the gut microbiome.

 

ENDS

 

Contacts

Origin Sciences Ltd
Tony Stephenson, Exitus Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel: +44 (0)7899 796655

 


 

6 January 2016

 

Origin Sciences Secures North American Distributor

 

London and Cambridge, UK, 6 January 2016: Origin Sciences Ltd, a medical technology company developing unique sampling devices and diagnostics for the stratification of patients with gastrointestinal diseases, has secured Metabiomics as a distributor for The United States of America.

 

Metabiomics is a US based, early stage molecular diagnostics company that is developing in-vitro diagnostics, screening tests, and health assays that leverage breakthroughs in next-generation DNA sequencing, computational systems biology, and human microbiome sciences.

 

The distribution agreement will see Metabiomics sell Origin’s products in North America for research into gastrointestinal diseases. These products include OriCol™, an effective, CE marked tool for sampling the rectal mucosa for investigating gastrointestinal disease, and the OriCol™ Microbiome Sampling Kit, which has been specifically designed for use in gut microbiome research, a fast-growing area of the life sciences industry.

 

Paul Weinberger, CEO of Origin Sciences said: “The North American market is one of the largest and fastest growing markets for both diagnostic and research kits for gastrointestinal disease. We are extremely pleased to have concluded this agreement, as expansion into North America is a key part of the commercialisation strategy for Origin. This follows a very successful year for Origin which as well as seeing increased uptake of the OriCol™ device, saw the launch of our Microbiome Sampling Kit.

 

Metabiomics President and COO, Greg Kuehn, added "Metabiomics is excited to offer the OriCol™ microbiome sampling kit for the development of new microbiome diagnostics and other applications. OriCol™ delivers a highly enriched and representative sample of the mucosa which may be an important advance over current stool sample and rectal swab methods used for studying the gut microbiome."

 

Since 2014 Origin has made significant progress in developing and commercialising its diagnostic technology.  2014 saw the launch of OriCol™, a sampling device for investigating gastrointestinal disease, while 2015 has seen the company expand its commercial presence to South East Asia and the US, and launch its Microbiome Research Kit. In addition, the company has been active in expanding its scientific research and has published data showing the benefits of using OriCol™ compared to traditional methods for research into the gut microbiome.

 

 

 

ENDS


 

 

Realising the potential of the microbiome 

 

07th December 2015 

 
 
 
Big pharma and venture capitalists alike are increasingly keen to understand and exploit the functions of genetic material of the microorganisms in the human body. More than 100 trillion microorganisms live in the gut, mouth, skin and other mucosal surfaces, providing a range of beneficial processes that could help medical advances. Antonia Twiston-Davies explains the latest developments.

The human microbiome is becoming increasingly important across the life sciences industry. Understanding this 'organ' has the potential to change how we treat a range of diseases and illnesses, in particular gastrointestinal (GI) diseases and related cancers. With this potential now much more widely understood, a number of large and smaller pharma companies have entered the market in the past few years.

While much of the original work has come from academia through initiatives such as the Human Microbiome Project, the commercial sector is now increasingly becoming involved. Johnson & Johnson (J&J) has been particularly active and has worked to forge a series of early-stage research alliances. January 2015 saw them partner with Vedanta Biosciences in a deal which will see J&J pay an undisclosed initial fee and as much as $241 million for Vendanta's mix of bacteria from the Clostridia subspecies that could be used as a treatment for Crohn's disease and ulcerative colitis. This follows a deal in 2013, in which J&J committed undisclosed upfront and future milestone payments to Second Genome for the programme focused on ulcerative colitis, a chronic condition in which the colon becomes inflamed.

In addition, Pfizer announced a collaboration with Second Genome in 2014, and Novartis and Roche have research teams active in this area.

The venture capital community has not been slow to spot the potential of the microbiome. The French venture capitalist company Seventure recently announced it had closed a new fund, Health for Life Capital, focused on four areas, one of which is the microbiome.

"Since 2008, we have noticed a steady growth of interest in the microbiome," said Isabelle de Cremoux, President and CEO at Seventure Partners, adding: "I expect to see more and more deals in this area, with Seventure being one of its main drivers."

At the same time, both medical device and diagnostics companies are entering this space. While the pharma companies are working on new treatments, there is a significant need for both diagnostic and research tools to investigate the role of the microbiome in health and disease. For example, Origin Sciences has launched a sampling device to assist in the standardised collection of the gut microbiome, while Paris-based Enterome is developing personalised tests and companion diagnostics to detect dysbiosis of the human gut microbiome.

Sampling methods

There have been vast improvements in how research in the area of GI diseases and related cancers is conducted. Currently, the most commonly-used gut sampling methods are stool sampling, rectal swabs and mucosal biopsy. Each of these has its own limitations and the storage and processing of samples all impact microbiota analysis.

Stool samples are convenient and low-cost, but they do not fully replicate the mucosal-associated bacterial profiles. In addition, stool samples are usually taken by the patient at home rather than immediately in the clinic. This can reduce compliance as some patients do not like handling stool samples. There are also risks of contamination during collection, delay in freezing the sample, variations in home freezer temperatures, and thawing during transport to the laboratory. Compelling evidence suggests that these factors may introduce sample variation large enough to compromise microbial diagnostics.

A biopsy of the intestinal mucosa would produce a standardised sample containing mucosally-adherent bacteria, although the bowel preparation required pre-biopsy may affect the microbiota profile. This sampling method is also invasive, expensive, time consuming and produces a very small sample which is difficult to process. Rectal swabs can be taken immediately in the clinic and stored in a standardised way, but the amount of material collected is considerably smaller than other methods, limiting its use in research.

There is a clear need to develop a sampling method that collects mucosal samples to adequately characterise the complex microbiota of the colon. It is also important to develop a standardised collection method and DNA extraction technique.

A prerequisite for using microbiota analysis as a clinical tool is efficient and consistent sampling and sample preservation. An important factor in this regard is the influence of sample handling and the effect of intestinal preparation by bowel cleansing on composition of microbiota in stool and the mucosal layer of the colon. An ideal sample type for use in routine diagnostics should be easy to obtain in a standardised fashion and reflect the microbiota in situ.

Fortunately, there are now several new tools being developed. Origin Sciences has produced one incorporating a nitrile membrane, which is inserted into the rectum via a standard proctoscope and inflated to make contact with the rectal mucosa. The membrane is then deflated and retracted into the device prior to removal from the patient, with the sample retained on the inverted membrane. It can be stored frozen or a suitable buffer added to preserve the material for subsequent analysis.

Micropharma has developed an ingestible medical device which can sample the mucosa at pre-determined locations throughout the GI tract, including the small intestine.

Despite its relative infancy, research into the human microbiome is becoming an increasingly important area, with significant sums being invested in both new treatments and new tools for research and diagnosis. While this is a complicated and difficult-to-research area, these new tools and techniques are making it possible to use the microbiome to develop effective new treatments for a range of GI diseases. Microbiome research may be in its infancy, but early indications are that it will grow to a significant sector, with not only the ability to treat directly-related illnesses, but also to impact more widely on human health.
 
                                                                                                                END

 

26th October 2015

Origin Sciences Launches Microbiome Sampling Kit

London and Cambridge, UK, 26th October 2015: Origin Sciences Ltd, a medical technology company developing unique sampling devices and diagnostics for the stratification of patients with gastrointestinal diseases, today announced the launch of the OriCol™ Microbiome Research Kit.

The OriCol™ Microbiome Research Kit has been specifically designed for use in gut microbiome research, a fast-growing area within the life sciences industry. Understanding the gut microbiome has the potential to change how a range of diseases and illnesses are treated, and in particular gastrointestinal diseases and related cancers.

The Microbiome Research Kit is an easy-to-use and effective tool for sampling rectal mucosa, which can be used to study the gut microbiome and how it correlates with factors including treatments, diet and disease. The mucosal samples obtained using the kit contain the established community of bacteria inhabiting the gut – including the same spectrum of bacteria as stool samples, which have been the traditional medium for study of the gut microbiome. However, the mucosal samples collected using Origin’s research kit, show an increased bacterial diversity and an enrichment of mucosal associated phyla. In addition, the reproducibility of sample collection and reduction in laboratory processing improves the quality of experimental data.

The OriCol™ Microbiome Research Kit has a number of advantages for both users and patients. The kit is simple to use, requires minimal training, and provides a method for rapid, on the spot sample collection. For patients, studies have found a high level of acceptability and compliance, as it is less invasive than traditional mucosal sampling techniques used and requires no bowel preparation.

Paul Weinberger, recently appointed CEO of Origin, said: “The microbiome is a growing area of research interest for the life sciences and pharmaceutical industries and has seen significant investment. However, it is a particularly challenging area to work in, and new tools and techniques are required. By using the OriCol™ Microbiome Research Kit, researchers can get better data, and improve their research, while also making sample collection less of a challenge for patients and researchers.”

Since 2014 Origin has made significant progress in developing and commercialising its diagnostic technology.  Last year saw the launch of OriCol™, a sampling device for investigating gastrointestinal disease, while 2015 has seen the company expand its commercial presence to South East Asia. In addition, the company has been active in expanding its scientific research and has published data showing the benefits of using OriCol™ compared to traditional methods for research into the gut microbiome.

ENDS

 

OriCol™ is a registered trademark of Origin Sciences Limited.

Notes to Editors:

For more information, please contact:

Tony Stephenson, Exitus Communications

This email address is being protected from spambots. You need JavaScript enabled to view it.

Tel: +44 (0)7899 796655

 

About Origin Sciences Limited

 

Origin Sciences is a medical technology company developing innovative devices and tests to aid the detection and diagnosis of gastrointestinal diseases. Origin Sciences is based in Cambridge and London, UK and was established in 2004. Origin Sciences has recently launched the OriCol™ device for reliable and superior clinical sampling of mucocellular rectal material. In addition, Origin Sciences has a portfolio of products in development including a test for the detection of colorectal cancer (CRC). Origin Sciences is ISO 13485 accredited and aims to be at the forefront of scientific breakthroughs in investigating gastrointestinal disease. For further information please visit www.originsciences.com

 


 

14 October 2015

 

Origin Sciences Appoints Paul Weinberger as CEO

 

London and Cambridge, UK, 14 October 2015: Origin Sciences Ltd, a medical technology company developing unique sampling devices and diagnostics for the stratification of patients with gastrointestinal diseases, has appointed Paul Weinberger as a company director and Chief Executive.

Paul joins Origin as the company prepares to develop and launch a series of new products using its novel sampling technology. Paul brings crucial sector expertise and commercial experience from a number of high level roles at companies including Lumora, Enigma Diagnostics and Roche Diagnostics. He remains as founder and Chief Executive of Diasolve, a company developing innovative medical technology for use in the cath lab, and serves as a member of both the NICE Diagnostics Advisory Committee and the board of BIVDA.

Commenting on his appointment, Paul Weinberger, said: “Origin is in an excellent position. Having developed some very strong sampling technology, it launched its first commercial product last year, and is now expanding its international sales and marketing presence. I am delighted to be joining at this critical time as the company moves to commercialise its products globally, and build on their unique capabilities to enable microbiome analysis and precision medicine for patients with gastrointestinal disease.”

Since 2014 Origin has made significant progress in developing and commercialising its diagnostic technology.  Last year saw the launch of OriCol™, a sampling device for investigating gastrointestinal disease, while 2015 has seen the company expand its commercial presence to South East Asia. In addition, the company has been active in expanding its scientific research and was able to publish data showing the benefits of using OriCol™ compared to traditional methods for research into gastrointestinal disease. 

OriCol™ is a registered trademark of Origin Sciences Limited.

 ENDS

Notes to Editors:

For more information, please contact:

Tony Stephenson, Exitus Communications

This email address is being protected from spambots. You need JavaScript enabled to view it.

Tel: +44 (0)7899 796655

 

About Origin Sciences Limited

Origin Sciences is a medical technology company developing innovative devices and tests to aid the detection and diagnosis of gastrointestinal diseases. Origin Sciences is based in Cambridge and London, UK and was established in 2004. Origin Sciences has recently launched the OriCol™ device for reliable and superior clinical sampling of mucocellular rectal material. In addition, Origin Sciences has a portfolio of products in development including a test for the detection of colorectal cancer (CRC). Origin Sciences is ISO 13485 accredited and aims to be at the forefront of scientific breakthroughs in investigating gastrointestinal disease. For further information please visit www.originsciences.com

 


 

 

06 May 2015

 

Origin Sciences Secures Distributor for South East Asia

 

London and Cambridge, 6st May 2015: Origin Sciences Ltd, a medical technology company developing innovative diagnostics and devices for investigating GI diseases, has expanded its global network with the appointment of AI Biomedical Pte Ltd as a distributor covering South East Asia.

The appointment, which begins on 1st May, will see AI-Biomedical Pte provided with the distribution rights for OriCol™ and other Origin products across South East Asia for three years. The countries in the agreement include Singapore, Thailand, Indonesia, Philippines, Vietnam, Malaysia, Brunei, Cambodia and East Timor. Origin is in further discussions with additional distributors in the Far East, and expects to announce these soon.

AI-Biomedical PTE Ltd. has a strong presence and network across South East Asia through the creation of a market for their own laboratory and diagnostic products.

 

Graham Griffiths, Commercial Director of Origin Sciences, said: “We are delighted to have secured AI Biomedical as our partner in South East Asia. The Asian market is a highly significant market which is developing rapidly. With recent data showing the effectiveness of OriCol™ as both a diagnostic and research tool for GI diseases, and particularly so in the rapidly growing area of microbiome, we expect to gain significant commercial traction through this distribution agreement.” 

Mr Chung-Pei, Chief Scientific Officer at AI-Biomedical, added: “Origin Sciences has developed an excellent device which we expect will receive significant interest from both the diagnostic and research markets. Having developed a strong network across South East Asia, we are very confident we can sell OriCol widely.”

OriCol™ was launched in July 2014, and since then has seen increased uptake both as a diagnostic and a research tool, globally. In addition, data published in 2015 showed the effectiveness of OriCol™ as a diagnostic and research tool in the rapidly expanding area of gut microbiome research.

Marketed as “the professional alternative to stool sampling”, OriCol™ is a CE-marked device that offers a simple, convenient and effective tool for sampling the rectal mucosa without the need for prior fasting or bowel preparation. Sampling can be performed by a trained healthcare professional in less than 5 minutes. The device incorporates a nitrile membrane, which after insertion into the rectum via a standard proctoscope, is inflated to make contact with the rectal mucosa. The membrane is then deflated and retracted into the device prior to removal from the patient. Upon retraction the material sampled from the rectal mucosa is retained on the inverted membrane. The device can either be stored frozen or a suitable buffer added to preserve the material for subsequent analysis.

 

 

ENDS 

 

OriCol™ is a registered trademark of Origin Sciences Limited.

 

Notes to Editors:

 For more information or for images of the OriCol™ device, please contact:

 Tony Stephenson, Exitus Communications

 This email address is being protected from spambots. You need JavaScript enabled to view it.

 Tel: +44 (0)7899 796655

 

 About Origin Sciences Limited

 Origin Sciences is a medical technology company developing innovative devices and tests to aid the detection and diagnosis of gastrointestinal diseases. Origin Sciences is based in Cambridge and London, UK and was established in 2004 as Colonix Limited before changing its name to Origin Sciences Limited in 2010. Origin Sciences has recently launched the OriCol™ device for reliable and superior clinical sampling of mucocellular rectal material. In addition, Origin Sciences has a portfolio of products in development including a test for the detection of colorectal cancer (CRC). Origin Sciences is ISO 13485 accredited. Origin Sciences aims to be at the forefront of scientific breakthroughs in investigating gastrointestinal disease. For further information please visit www.originsciences.com

 


 

 

01 April 2015

 

Newly-Published Data Shows the Effectiveness of OriCol™ for Sampling the Gut Microbiome

 

London and Cambridge, 1st April 2015 : Origin Sciences Ltd, a medical technology company developing innovative diagnostics and devices for investigating GI diseases, has published new data showing the effectiveness of its OriCol™ sampling device in gut microbiome research and development.

The trial compared the microbiome profile of OriCol™ and stool samples taken at three different time points from healthy subjects. A single rectal swab sample was also obtained from each subject. The microbiome data, which was produced and analysed by Second Genome, Inc., showed that the range and trends in alpha diversity between subjects were mirrored in OriCol™ and stool samples, however the rectal swab samples showed lower diversity. Whole microbiome abundance profiles were significantly different between OriCol™ and stool samples when grouped by subject or sample type. Whilst specific families of bacteria belonging to the phyla Bacteriodetes, Firmicutes and Proteobacteria were enriched in OriCol™ samples, other families of bacteria belonging to the phyla Actinobacteria as well as different families within the Bacteriodetes phyla were enriched in stool. Subject to subject comparisons demonstrated that the OriCol™ device is able to capture donor-to-donor differences found in stool samples, but the microbial community differs in the two sample types.

Scientific Director at Origin Sciences, Dr Jodie Booth commented, “This new data shows OriCol™ as a valuable tool in the exciting and dynamic area of microbiome research and development. The gut microbiome is becoming an increasingly important component of research into diagnosis and treatments of gastrointestinal diseases, but research using traditional sampling methods can be challenging. OriCol™ presents a novel methodology for reliably sampling the gut microbiome.

Graham Griffiths, Commercial Director added: “The results of this study highlight how important OriCol™ will be in the development of new diagnostics and treatments based on the gut microbiome. This encouraging data provides an opportunity to provide a dedicated OriCol™ sampling and stabilisation kit, enabling researchers’ simple and convenient access to gut microbiome profiles. We aim to make OriCol™ the gold standard for effective gut microbiome sampling.”

OriCol™ is a CE-marked device that offers a simple, convenient and effective tool for sampling the rectal mucosa without the need for prior fasting or bowel preparation. Sampling can be performed by a trained healthcare professional in less than 5 minutes. The device incorporates a nitrile membrane, which after insertion into the rectum via a standard proctoscope, is inflated to make contact with the rectal mucosa. The membrane is then deflated and retracted into the device prior to removal from the patient. Upon retraction the material sampled from the rectal mucosa is retained on the inverted membrane. The device can either be stored frozen or a suitable buffer added to preserve the material for subsequent analysis.

OriCol™ was launched in July 2014, and since then has seen increased uptake both as a diagnostic and a research tool, globally.

 

ENDS

 

OriCol™ is a registered trademark of Origin Sciences Limited.

Notes to Editors:

For more information or for images of the OriCol™ device, please contact:

Tony Stephenson, Exitus Communications

This email address is being protected from spambots. You need JavaScript enabled to view it.

Tel: +44 (0)7899 796655

About Origin Sciences Limited

Origin Sciences is a medical technology company developing innovative devices and tests to aid the detection and diagnosis of gastrointestinal diseases. Origin Sciences is based in Cambridge and London, UK and was established in 2004 as Colonix Limited before changing its name to Origin Sciences Limited in 2010. Origin Sciences has recently launched the OriCol™ device for reliable and superior clinical sampling of mucocellular rectal material. In addition, Origin Sciences has a portfolio of products in development including a test for the detection of colorectal cancer (CRC). Origin Sciences is ISO 13485 accredited. Origin Sciences aims to be at the forefront of scientific breakthroughs in investigating gastrointestinal disease. For further information please visit www.originsciences.com


 

23 September 2014

 Origin Sciences wins Cambridge Innovation Award for OriCol™ sample collection device

 

London and Cambridge, UK, 23 September 2014:

Origin developed OriCol™ based on feedback from GI, Oncology and other experts that there exist major gaps in the current model of disease detection based on stool sampling. To address market need, Origin Sciences developed the novel OriCol™ sampler that allows physicians to easily and securely collect samples of the full rectal mucosa for a range of high-value screening tests and analyses. The product allows physicians and nurse practitioners access to key patient samples to be used in combination with a variety of screening modalities including genomic-based assays, morphology and chemical detection of cancers. Using the OriCol technology, Origin is developing a portfolio of assays and seeking collaborations to develop high-value diagnostic tests for the GI market. Origin’s first assay in development will identify a primary marker for IBD, calprotectin. Additional Origin and partnered assays will include tests based on gut microbiome and tests for colorectal cancer.

OriCol™ has a high level of patient acceptability and no preparation of the bowel is required. The sampling can be carried out by a trained healthcare professional within five minutes. The OriCol™ device offers a convenient, minimally invasive alternative to stool collection and provides a sample rich in cells, nucleic acids, proteins, mucus, microorganisms (gut microbiome) and some faecal matter. 

Scientific Director at Origin Sciences, Dr Jodie Booth comments “We are thrilled to receive this award and to be recognised for our novel OriCol™ device, which has the potential to vastly improve the way clinical samples are taken for the diagnosis of GI diseases.”

  ENDS


 

17 June 2014

Origin Sciences launches OriCol™, an innovative sampling device to enable investigations in Gastrointestinal (GI) disease

London and Cambridge, UK, 17 June 2014: Origin Sciences Ltd, a medical technology company developing innovative devices for investigating GI diseases, has today announced the launch of their new OricCol™ sample collection device. OriCol™ enables the convenient and effective sampling of mucocellular material that has migrated along the entire colon to the rectum. The OriCol™ device is CE marked and collects biologically informative samples containing a range of biomarkers to enable clinical analysis and research into GI conditions.

Analysis of stool-based biomarkers is widely used in clinical practice to provide information about a range of GI conditions and diseases such as Irritable Bowel Syndrome (IBS), Colorectal Cancer (CRC) and Inflammatory Bowel Disease (IBD).  However, stool collection is inconvenient for both doctors and patients and presents various handling and processing challenges. The OriCol™ device offers a convenient, minimally invasive alternative to stool collection and provides a sample rich in cells, nucleic acids, proteins, mucus, microorganisms (gut microbiome) and some faecal matter.  

The OriCol™ device is inserted into the rectum using a proctoscope and then the OriCol™ membrane is inflated with air using a syringe. The membrane collects an imprint of valuable material from the mucocellular layer, after which the membrane is deflated and the device removed. A short animation shows how the device works, http://youtu.be/R-Ug_sJU9fE. OriCol™ has been tested in several patient cohorts comprising more than 2,500 subjects. The procedure is well tolerated by patients with >86% reporting no discomfort. The test can be performed very simply and quickly by a trained healthcare professional without any prior bowel preparation.

Mr Jon Lacy-Colson, Colorectal Surgeon comments on the OriCol™ device "Our network has been conducting research with this device to analyse protein and DNA biomarkers. The OriCol™ device is tolerated well by patients and is very simple and convenient to use and we recognise its broad potential as a tool for both gastrointestinal research and clinical use."

“We successfully used the OriCol™ device in a clinical trial assessing shed cells from the gut. The device was easy to use, caused no patient discomfort above a standard rectal examination and we had no untoward events. As a method to collect cellular material and expressed proteins, we recommend the OriCol™ device from Origin Sciences” added Ian Daniels FRCS, Consultant Colorectal Surgeon, Exeter.

Scientific Director at Origin Sciences, Dr Jodie Booth adds “The device has all the benefits of ease of use, compliance, patient acceptability, and the collection of a wide range biomarkers which can be readily analysed. The OriCol™ device has the potential to change the way clinical samples are taken for the diagnosis and monitoring of GI diseases and companion diagnostics”.

Origin Sciences will be launching the OriCol™ device during the British Society of Gastroenterology (BSG) Annual Meeting on 17-19 June 2014, Manchester. On 18 June 12.30-14.00, Dr Booth will be presenting at the BSG Poster Session, No. PWE-008: “A novel sampling device for collecting mucocellular material from the rectum”. Please visit us at booth number A13E to learn more about OriCol™ and Origin Sciences.

ENDS

OriCol™ is a registered trademark of Origin Sciences Limited.

Notes to Editors:

For more information or for images of the OriCol™ device, please contact:

Tony Stephenson, Exitus Communications

This email address is being protected from spambots. You need JavaScript enabled to view it.

Tel: +44 (0)7899 796655

 

Jenny Searle, Origin Sciences Ltd

This email address is being protected from spambots. You need JavaScript enabled to view it.

 

About Origin Sciences Limited

Origin Sciences is a medical technology company developing innovative devices and tests to aid the detection and diagnosis of gastrointestinal diseases. Origin Sciences is based in Cambridge and London, UK and was established in 2004 as Colonix Limited before changing its name to Origin Sciences Limited in 2010. Origin Sciences has recently launched the OriCol™ device for reliable and superior clinical sampling of mucocellular rectal material. In addition, Origin Sciences has a portfolio of products in development including a test for the detection of colorectal cancer (CRC). Origin Sciences is ISO 13485 accredited. Origin Sciences aims to be at the forefront of scientific breakthroughs in investigating gastrointestinal disease.

 

Please follow us on LinkedIn and Twitter to receive updates from Origin Sciences